Summary
The possibility of an inhibitory effect of spironolactone on the biliary clearance of digoxin has been investigated in 6 healthy subjects.
Plasma clearance and the renal and biliary clearance of digoxin were determined twice at steady state (digoxin 0.5 to 1 mg·d−1 p.o. for 6 days), alone or in combination with spironolactone 200 mg daily, after an intravenous dose of digoxin (0.7 × oral dose) on Day 7. Plasma and urine were collected for 48 h. Biliary clearance of digoxin was determined on Day 8 by a duodenal perfusion technique.
During spironolactone treatment plasma digoxin clearance tended to be lower (255 vs 224 ml/min; P=0.057) and renal clearance significantly lower (166 vs 144 ml/min), while the biliary clearance of digoxin remained unchanged (106 vs 103 ml/min).
Thus, spironolactone reduced the renal clearance of digoxin by an average of 13%, without affecting its biliary clearance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abshagen U, Rennekamp H, Luszipinski G (1976) Pharmacokinetics of spironolactone in man. Naunyn Schmiedeberg's Arch Pharmacol 296: 37–45
Abshagen U, von Grodzicki U, Hirschberger U, Rennekamp H (1977) Effect of enterohepatic circulation on the pharmacokinetics of spironolactone in man. Naunyn Schmiedeberg's Arch Pharmacol 300: 281–287
Angelin B, Arvidsson A, Dahlqvist R, Hedman A, Schenck-Gustafsson K (1987) Quinidine reduces biliary clearance of digoxin in man. Eur J Clin Invest 17: 262–265
Bergman A, Öhman G (1980) Effect of detergent on kinetic Jaffémethod assay of creatinine. Clin Chem 26: 1729–1732
Erttmann RR, Damm KH (1975) On the problem of a common hepatic transport process for steroids. Uptake of 3H-ouabain, 3H-taurocholic acid and 3H-corticosterone into rat liver slices. Arch Int Pharmacodyn Ther 214: 232–239
Fenster PE, Hager WD, Goodman MM (1984) Digoxin-quinidine-spironolactone interaction. Clin Pharmacol Ther 36: 70–73
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edition, Dekker, New York
Hedman A, Angelin B, Arvidsson A, Dahlqvist R, Nilsson B (1990) Interactions in the renal and biliary elimination of digoxin: Stereoselective difference between quinine and quinidine. Clin Pharmacol Ther 47: 20–26
Hedman A, Angelin B, Arvidsson A, Beck O, Dahlqvist R, Nilsson B, Olsson M, Schenck-Gustafsson K (1991a) Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 49: 256–262
Hedman A, Angelin B, Arvidsson A, Dahlqvist R (1991b) No effect of probenecid on the renal and biliary clearances of digoxin in man. Br J Clin Pharmacol 32: 63–67
Kupferberg HJ, Schanker LS (1968) Biliary secretion of ouabain-3H and its uptake by liver slices in the rat. Am J Physiol 214: 1048–1053
Kupferberg HJ (1969) Inhibition of ouabain-3H uptake by liver slices and its excretion into the bile by compounds having a steroid nucleus. Life Sci 8: 1179–1185
Masson JP, Bass O, Baur HR, Ohnhaus EE (1978) Zur Eliminations-kinetik des Digoxin vor und während Spironolactonbehandlung. Klin Wochenschr 56: 1071–1076
Morris RG, Lagnado PY, Lehmann DR, Frewin DB, Glistak ML, Burnet RB (1987) Spironolactone as a source of interference in commercial digoxin immunoassays. Ther Drug Monit 9: 208–211
Nilsell K, Angelin B, Leijd B, Einarsson K (1983) Comparative effect of ursodeoxycholic acid and chenodeoxycholic acid on bile acid kinetics and biliary lipid secretion in humans. Evidence for different modes of action on bile acid synthesis. Gastroenterology 85: 1248–1256
Overdiek JW, Hermens WA, Merkus FW (1985a) Determination of the serum concentration of spironolactone and its metabolites by high-performance liquid chromatography. J Chromatogr 341: 279–285
Overdiek HW, Hermens WA, Merkus FW (1985b) New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther 38: 469–474
Phillips AP (1973) The improvement of specificity in radioimmunoassays. Clin Chim Acta 44: 333–340
Pleasants RA, Williams DM, Porter RS, Gadsden RH (1989) Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays. Ther Drug Monit 11: 200–204
Rao ML, Rao GS, Höller M, Breuer H, Schattenberg PJ, Stein WD (1976) Uptake of cortisol by isolated rat liver cells a phenomenon indicative of carrier-mediation and simple diffusion. Z Physiol Chem 357: 573–584
Rao ML, Rao GS, Breuer H (1977) Uptake of estrone, estradiol-17beta and testosterone by isolated rat liver cells. Biochem Biophys Res Commun 77: 566–573
Rodin SM, Johnson BF (1988) Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 15: 227–244
Schanker LS (1968) Secretion of organic compounds in bile. In Handbook of Physiology (6): V. Alimentary Canal; Chapt 114. ed Code, CF, pp 2433–2449. American Physiological Society, Washington DC
Steiness E (1974) Renal tubular secretion of digoxin. Circulation 50: 103–107
Taylor SA, Rawlins MD, Smith SE (1972) Spironolactone — a weak enzyme inducer in man. J Pharm Pharmacol 24: 578–579
Thomas RW, Maddox RR (1981) The interaction of spironolactone and digoxin: A review and evaluation. Ther Drug Monit 3: 117–120
Vetticaden SJ, Barr WH, Beightol LA (1986) Improved method for assaying digoxin in serum using high-performance liquid chromatography — radioimmunoassay. J Chromatogr 383: 187–193
Waldorff S, Damgaard Andersen J, Heeboll-Nielsen N, Gamborg Nielsen O, Moltke E, Sorensen U, Steiness E (1978) Spironolactone-induced changes in digoxin kinetics. Clin Pharmacol Ther 24: 162–167
Wirth KE, Frölich JC (1974) Effect of spironolactone on excretion of 3H-digoxin and its metabolites in rats. Eur J Pharmacol 29: 43–51
Wirth KE, Frölich JC, Hollifield JW, Falkner FC, Sweetman BS, Oates JA (1976) Metabolism of digitoxin in man and its modification by spironolactone. Eur J Clin Pharmacol 9: 345–354
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hedman, A., Angelin, B., Arvidsson, A. et al. Digoxin-interactions in man: Spironolactone reduces renal but not biliary digoxin clearance. Eur J Clin Pharmacol 42, 481–485 (1992). https://doi.org/10.1007/BF00314854
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00314854